Short answer
Inhibikase Therapeutics, Inc. (IKT) filed its Q3 2025 10-Q quarterly report on Nov 14, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$12M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$12M
- −106.5% YoY · −20.3% QoQ
- EPS (diluted)
- −$0.14
- +78.5% YoY · −27.3% QoQ
Source: XBRL data from the Inhibikase Therapeutics, Inc. (IKT) Q3 2025 10-Q on SEC EDGAR. USD.
Inhibikase Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: U.S. federal government shutdown beginning after September 30, 2025, potentially delaying FDA reviews and regulatory submissions
- Regulatory risk: Executive Orders 14273 and 14297 directing drug-price reductions, including most-favored-nation pricing targets
- Operational risk: Product candidates manufactured in China, exposing supply continuity to tariffs and geopolitical restrictions
- Compliance risk: DOJ data-transfer rules restricting sensitive health and genetic data transactions involving China
- Financial risk: OBBBA changes to research-and-development tax deductions, affecting future cash flow
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Inhibikase Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.